These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 15370671)

  • 21. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
    Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
    Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections.
    Garbino J; Villiger P; Caviezel A; Matulionyte R; Uckay I; Morel P; Lew D
    Infection; 2007 Jun; 35(3):161-6. PubMed ID: 17565457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febrile neutropenia in haematological malignancies.
    Sharma A; Lokeshwar N
    J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].
    Bosseray A; Nicolini F; Brion JP; Michallet M; Hollard D; Stahl JP; Micoud M
    Pathol Biol (Paris); 1992 Oct; 40(8):797-804. PubMed ID: 1484739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.
    El-Maghraby SM; Moneer MM; Ismail MM; Shalaby LM; El-Mahallawy HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):131-6. PubMed ID: 17356388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
    Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
    Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
    Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
    Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.
    Egerer G; Goldschmidt H; Hensel M; Harter C; Schneeweiss A; Ehrhard I; Bastert G; Ho AD
    Bone Marrow Transplant; 2002 Oct; 30(7):427-31. PubMed ID: 12368954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Hidalgo M; Hornedo J; Lumbreras C; Trigo JM; Colomer R; Perea S; Gómez C; Ruiz A; García-Carbonero R; Cortés-Funes H
    Cancer; 1999 Jan; 85(1):213-9. PubMed ID: 9921995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cherif H; Johansson E; Björkholm M; Kalin M
    Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.